Entero Healthcare Solutions FY26 Results

Consolidated Revenue: ₹6,591.21 crore
Consolidated Net Profit: ₹145.84 crore

Reader Takeaway: Strong revenue growth and MedTech pivot are positives; acquisition integration is a key watch point.

What just happened

Entero Healthcare Solutions reported consolidated revenue of ₹6,591.21 crore for the fiscal year 2025-26, a 29.35% increase from the previous year's ₹5,095.78 crore. Net profit after tax surged by 35.75% to ₹145.84 crore. The company also achieved positive operating cash flow of ₹96.20 crore, a significant turnaround from an outflow of ₹76.90 crore in the prior fiscal.

Why this matters

The robust revenue growth highlights Entero's success in capturing market share in India's fragmented healthcare distribution sector, supported by both organic expansion and strategic acquisitions. The substantial rise in net profit indicates improved operational efficiency and profitability. The positive operating cash flow is a critical milestone, reducing the company's reliance on external funding and signaling better financial health.

The backstory

Entero Healthcare Solutions is a key player in pharmaceutical distribution. The company has been actively pursuing a growth strategy involving both organic expansion and inorganic acquisitions to consolidate its presence and product portfolio. Its recent focus has been on expanding into the MedTech segment, which offers higher margins.

What changes now

The company's strategic pivot into MedTech, covering diagnostics, medical devices, cardiology, orthopaedics, and imaging, is expected to contribute over ₹1,000 crore in annualized revenue by FY27. This move aims to enhance the company's overall margin profile. The company also fully utilized its IPO net proceeds of ₹954.80 crore for its growth initiatives.

Risks to watch

Entero completed seven strategic acquisitions in FY26. The aggressive acquisition strategy presents integration risks, including challenges in system unification, realizing operational synergies, and retaining key personnel. Additionally, the upfront investment required for MedTech expansion in sales and marketing could temporarily affect short-term margins.

Peer comparison

Entero's 29.35% revenue growth for FY26 significantly outpaces the broader Indian Pharmaceutical Market (IPM), indicating strong competitive performance. Specific peer comparisons are not detailed in the filing, but the company's strategic moves suggest it aims to differentiate itself through a diversified product mix and an expanded distribution network.

Context metrics (time-bound)

Consolidated Revenue FY26: ₹6,591.21 crore (vs. ₹5,095.78 crore FY25)
Consolidated Net Profit FY26: ₹145.84 crore (vs. ₹107.43 crore FY25)
Operating Cash Flow FY26: ₹96.20 crore (vs. ₹-76.90 crore FY25)
MedTech annualized revenue outlook (FY27): >₹1,000 crore
Net working capital days: 59 days (end Q4 FY26)
ROCE: 14.6%
ROE: 12.5%

What to track next

Investors should monitor Entero Healthcare's ability to successfully integrate its seven recent acquisitions. Continued margin expansion, sustained positive cash flow generation, and the realization of revenue targets from the MedTech segment will be key performance indicators to watch in the upcoming fiscal year.